Carl Zeiss Meditec (AFX) AGM Presentation summary

Financial performance

• Achieved €2,066.1 million in revenue for fiscal year 2023/24.

• EBITA reached €248.9 million with a 12.0% EBITA margin in 2023/24.

• Q1 2024/25 revenue was €490.5 million, up 3.2% year-over-year.

• Q1 2024/25 EBITA was €35.2 million with a 7.2% margin.

• Dividend per share set at €0.60.

Regional sales and growth

• APAC contributed €949.0 million in sales, representing 45.9% of total revenue, with a -5.2% sales growth.

• EMEA generated €584.3 million in sales (28.3% of total), growing 12.9%.

• Americas accounted for €532.9 million in sales (25.8% of total), with a -6.6% sales growth.

Operational efficiency and resilience

• Operating expenses decreased by 1.2% year-over-year, from €853 million to €843 million (excluding DORC).

• Short-term measures include expense reviews, focus on innovation, and restrictive recruitment.

• Mid-term actions target productivity, process optimization, and employee training.